Phase 3 NAVIGATOR trial of tezepelumab meets primary endpoint of reduction in exacerbations in broad range of patients with severe asthma
In this RCT (n=1,061), tezepelumab, afirst-in-class thymic stromal lymphopoietin inhibitor,added to standard of care (SoC) showed a statistically significant reduction vs. placebo plus SoC in annualised asthma exacerbation rate over 52 weeks.
Source:
Biospace Inc.